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Abstract
Inter-organellarQ1 communication often takes the form of Ca
2+ signals. These Ca2+ signals originate from the endoplasmic
reticulum (ER) and regulate different cellular processes like metabolism, fertilization, migration, and cell fate. A prime
target for Ca2+ signals are the mitochondria. ER–mitochondrial Ca2+ transfer is possible through the existence of
mitochondria-associated ER membranes (MAMs), ER structures that are in the proximity of the mitochondria. This creates
a micro-domain in which the Ca2+ concentrations are manifold higher than in the cytosol, allowing for rapid
mitochondrial Ca2+ uptake. In the mitochondria, the Ca2+ signal is decoded differentially depending on its
spatiotemporal characteristics. While Ca2+ oscillations stimulate metabolism and constitute pro-survival signaling,
mitochondrial Ca2+ overload results in apoptosis. Many chemotherapeutics depend on efﬁcient ER–mitochondrial Ca2+
signaling to exert their function. However, several oncogenes and tumor suppressors present in the MAMs can alter Ca2+
signaling in cancer cells, rendering chemotherapeutics ineffective. In this review, we will discuss recent studies that
connect ER–mitochondrial Ca2+ transfer, tumor suppressors and oncogenes at the MAMs, and chemotherapy.
Facts
● Ca2+ ﬂuxes between ER and mitochondria affect
several cancer hallmarks, including apoptosis
resistance, migration, and invasion.
● Oncogenes and tumor suppressors residing at the
MAMs execute part of their cellular function by
altering ER–mitochondrial Ca2+ transfer, thereby
promoting or preventing cancer cell survival.
● Dependent on the cancer type and cancer stage,
ER–mitochondrial Ca2+ transfer can either exert
anti-tumorigenic effects like restoring apoptosis
sensitivity or exert pro-tumorigenic effects like
promoting metastatic behavior.
● Different chemotherapeutics rely on a Ca2+-signaling
component to induce cancer cell death.
● Ca2+ signaling modulation can (re)sensitize or
increase the responsiveness of cancer cells towards
chemotherapeutics.
Open questions
● How can Ca2+ signaling at ER–mitochondrial contact
sites be modulated in a cancer-speciﬁc manner to
ﬁght cancer cell survival?
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● Can ER–mitochondrial Ca2+ signaling events
overcome dysregulated cell survival/apoptosis
sensitivity in cells with altered oncogene and/or
tumor suppressor function?
● What processes/regulation pathways underlie or
control differences between ER–mitochondrial Ca2+
transfer in cancer cells vs. normal cells?
● How can Ca2+-signaling modulation be applied to
increase responsiveness and sensitivity to existing
therapies and to induce cancer cell-speciﬁc cell death
while sparing normal cells?
● Can Ca2+ signaling be applied in a cancer stage-
speciﬁc manner, thereby promoting cell death and
avoiding metastasis?
● What other molecular mechanisms, like the
generation of ROS, exchange of lipids or alterations
in protein composition, or ER–mitochondrial
tethering at the MAMs impact or cooperate with
Ca2+ signaling in anti-cancer chemotherapeutic
actions?
Introduction: ER–mitochondrial Ca2+ signaling in
cell death and survival
Mitochondria do not only fulﬁll the function of pow-
erhouse of the cell but their function also encompasses
more than merely providing the cell with ATP1,2. Cur-
rently, mitochondrial function has been implicated in
apoptosis, autophagy, cell proliferation, cellular senes-
cence, and migration3–6. Furthermore, mitochondrial
function is impacted by the “state” of the mitochondrial
network, which can range from highly connected to
fragmented7. Nevertheless, mitochondria do not act as
sole orchestrators of cellular processes. In fact, the
mitochondrial network rather functions as a highly ver-
satile signaling platform, closely connected to other cell
organelles, like the endoplasmic reticulum (ER)8 and
peroxisomes9. To allow for inter-organellar cross-talk, the
different organelles are often located in close proximity to
each other10,11, like the ER and the mitochondria, which
are connected through mitochondria-associated ER
membranes (MAMs). These MAMs are deﬁned as ER
membranes that are in close apposition (10–50 nm) to the
mitochondria and were ﬁrst isolated as a distinct entity in
the early 1990s11–13. In recent years, MAMs were shown
to contribute to various cellular functions like metabo-
lism, autophagy, lipid synthesis but also cell survival and
cell death8,14–18. In this sense, the MAMs, like mito-
chondria, are highly dynamic signaling hubs where signals
from different cellular pathways converge and are inte-
grated15,19–21.
One of the signals transferred between ER and mito-
chondria at the MAMs is the ubiquitous second mes-
senger Ca2+22,23. While [Ca2+] in the cytosol is
maintained at low levels under resting conditions, the
bulk of intracellular Ca2+ is conﬁned in the ER22. Ca2+ is
predominantly released from the ER via the inositol 1,4,5-
trisphosphate (IP3) receptor (IP3R), which is gated by
IP3
24, or the ryanodine receptor (RyR)25. However, Ca2+
accumulation into the mitochondrial matrix requires
Ca2+ transport across the outer mitochondrial membrane
(OMM) and the inner mitochondrial membrane (IMM).
At the OMM, Ca2+ transport is mediated via the high-
conductance voltage-dependent anion channel 1
(VDAC1), while at the IMM, Ca2+ transport is mediated
via the mitochondrial Ca2+ uniporter (MCU), the pore-
forming unit in the MCU complex, consisting of MCU
itself and its regulators26–28. For a detailed description of
MCU regulation we would like to refer to refs. 29,30. The
MAMs play an important role in mitochondrial Ca2+
uptake, since they provide a Ca2+ micro-domain, where
Ca2+ levels are higher than in the bulk cytosol1,15. This is
necessary to sustain ER–mitochondrial Ca2+ signaling
since the MCU has a low afﬁnity for Ca2+. Thus, the
MAMs allow for efﬁcient, ‘quasi-synaptic’ mitochondrial
Ca2+ uptake upon ER Ca2+ release through the formation
of a micro-domain1,15,31. This emphasizes the importance
of the MAMs as a signaling hotspot.
Mitochondrial Ca2+ signals are decoded differentially
depending on their spatiotemporal characteristics (see
Fig. 1). For example, cytosolic Ca2+ oscillations, efﬁciently
transferred to the mitochondria through these contacts
sites, drive mitochondrial metabolism. Moreover, several
mechanisms account for the dynamic interplay between
Ca2+ signals and mitochondrial metabolism. Ca2+ increa-
ses the activity of several rate-limiting enzymes of the tri-
carboxylic acid (TCA) cycle, including pyruvate, isocitrate,
and α-ketoglutarate dehydrogenases32, while MCU tran-
scription is controlled by the cAMP-responsive element
binding protein, a Ca2+-dependent transcription factor33.
Cells can also ﬁne tune the level of Ca2+ oscillations that
drive mitochondrial bioenergetics via a redox-nano-
domain34. Mitochondrial Ca2+ uptake triggers K+- and
H2O-inﬂux into the mitochondrial matrix, leading to
cristae compression and H2O2 release at the MAMs. This
provides positive feedback on IP3Rs, enhancing their ability
to sustain Ca2+ oscillations34. Other contributions of Ca2+
to cell metabolism are the stimulation of complex III of the
electron transport chain, as well as stimulation of the ATP
synthase and the adenine nucleotide translocase35.
Ca2+ oscillations in the cytosol can also modify mito-
chondrial metabolism indirectly by activating ARALAR, a
mitochondrial glutamate/aspartate transporter playing a
central role in the malate/aspartate shuttle, which is
strongly dependent on cytosolic Ca2+ signaling36. Ca2+
binds to ARALAR and activates ARALAR-mediated
glutamate and NAD(P)H transport into the mitochon-
dria36–38. Also, pyruvate production is Ca2+ dependent
and is linked to the malate/aspartate shuttle, providing
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pyruvate to the mitochondria39,40. In addition, there is
tissue-speciﬁc regulation, which determines the threshold
for mitochondrial Ca2+ inﬂux and its effects41. Liver cells
and cardiomyocytes contain a high and a low ratio of
mitochondrial Ca2+ uptake 1 (MICU1)/MCU, respec-
tively, with MICU1 (together with MICU2) being an
MCU regulator which affects the cooperativity of mito-
chondrial Ca2+ uptake42,43. Therefore liver cells display a
high cooperativity of mitochondrial Ca2+ uptake, while
cardiac cells display a low cooperativity. This prevents the
occurrence of mitochondrial Ca2+ signals in response to
short-lasting Ca2+ transients and thus avoids mitochon-
drial Ca2+ overload even when the heart beats at high
frequency41. Recently, it was shown that apart from
affecting the cooperativity of mitochondrial Ca2+ uptake,
MICU1, together with its paralog MICU2, inhibits the
MCU at cytosolic Ca2+ concentrations lower than ~600
nm, thereby determining the relatively high threshold for
MCU-mediated Ca2+ uptake44. Compared to wild-type
cells, loss of MICU1, which also results in loss of MICU2,
lowers the threshold for MCU-mediated mitochondrial
Ca2+ uptake to about 200 nM Ca2+. Compared to
mitochondria lacking both MICU1 and MICU2, mito-
chondria containing MICU1 but not MICU2 display a
higher threshold for mitochondrial Ca2+ uptake (~350
nM Ca2+), indicating that MICU1 by itself can inhibit
MCU. These observations indicate that MICU1 does not
only control MCU cooperativity43, but can also function
as a gatekeeper of MCU44. Moreover, MICU2 requires
MICU1 to regulate MCU. MICU1’s function as a gate-
keeper is also important in vivo to prevent mitochondrial
Ca2+ overload, as evidenced in MICU1-knockout ani-
mals, developing ataxia and muscle fatigue associated
with elevated mitochondrial Ca2+ levels and reduced
ATP levels45. Finally, MICU1 and MICU2 were shown to
bind the mitochondrial lipid cardiolipin, facilitating
membrane anchoring of the complex and the ﬁne-tuned
Ca2+-dependent regulation of the MCU by MICU1 and
associated factors, like EMRE44.
On the other hand, massive Ca2+ release from the ER
causes mitochondrial Ca2+ overload, resulting in opening
of the mitochondrial permeability transition pore
(mPTP)46,47, mitochondrial swelling, and subsequent cell
death (Fig. 1)48–51. Several mechanisms may account for
Fig. 1 Ca2+ signaling at the ER and the mitochondria in cell death and survival. Arrow-headed lines indicate a stimulatory or consequential
effect. The ER is the main intracellular Ca2+ storage organelle. The release of Ca2+ from this organelle is mediated by the IP3R, gated by the
intracellular messenger IP3. Ca
2+ then travels via VDAC1, which is physically coupled to the IP3R through GRP75, and MCU to the mitochondrial
matrix. Ca2+ oscillations targeted to the mitochondria are able to stimulate mitochondrial metabolism in several ways. Firstly, the TCA has three rate-
limiting enzymes that are regulated by Ca2+: pyruvate dehydrogenase, isocitrate dehydrogenase, and α-ketoglutarate dehydrogenase. Furthermore,
both the ATP synthase and complex III of the electron transport chain (ETC) are stimulated by Ca2+. In addition, the adenine nucleotide translocase
(ANT) is activated as well. Interestingly, positive feedback mechanisms exist to ensure Ca2+ feeding into the mitochondria. One of these mechanisms
is dependent on a redox-nano-domain at the MAMs: Ca2+ inﬂux into the mitochondrial matrix activates Ca2+-activated K+ channels and parallel H2O
uptake in the mitochondria. This results in cristae compression (indicated by the red arrows) and H2O2 extrusion, which stimulates IP3R activity. In
short, by stimulating cellular metabolism, Ca2+ oscillations contribute to cell survival. However, excessive Ca2+ uptake in the mitochondria causes
mitochondrial Ca2+ overload. This results in opening of the mPTP, either by a direct action of Ca2+ on the mPTP or by Ca2+ binding to cardiolipin,
thereby disrupting complex II of the ETC and subsequent ROS production. mPTP opening leads to mitochondrial swelling, rupture of the OMM, and
release of pro-apoptotic factors like cytochrome c and ultimately apoptosis
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this. For instance, mitochondrial Ca2+ inﬂux results in
Ca2+ binding to cardiolipin, causing the disintegration of
complex II and the release of the functionally active cat-
alytic subunits in the mitochondrial matrix, providing a
source of reactive oxygen species (ROS) that triggers the
opening of the mPTP52. In addition to this, recent evi-
dence emerged that mitochondrial Ca2+ could directly
target the mPTP, resulting in a conformational change
leading to its opening and to subsequent mitochondrial
swelling53.
Regulation of ER–mitochondrial Ca2+ signaling at
the MAMs
Given its critical role in cell fate and survival, the
composition and functional properties of the MAMs have
to be carefully regulated and controlled. This occurs
through a distinct set of proteins with a variety of cell
biological properties and functions. Some of these pro-
teins are directly involved in Ca2+ signaling at the MAMs,
e.g. the IP3R and VDACs
49,54,55, whereas others alter
ER–mitochondrial Ca2+ signaling by acting through
modulation of these Ca2+-transport systems, e.g. pro-
myelocytic leukemia protein (PML)56 or phosphatase and
tensin homolog (PTEN)57. Other proteins modify the
characteristics of the MAMs (e.g. their distance to the
mitochondria), like the ER–mitochondria tethers
mitofusin-2 (Mfn-2)58,59, the protein kinase RNA-like
endoplasmic reticulum kinase (PERK)60, and the spacer
protein fetal and adult testis expressed 1 (FATE1)61. We
will focus on the proteins involved in ER–mitochondrial
Ca2+ transfer at the MAMs, yet for a more extensive list
of proteins present at the MAMs, we refer to ref. 13. For
further insights on the role of Ca2+-transport systems in
cell death and survival, we refer to ref. 62. All the MAM
components discussed in this section are schematically
depicted in Fig. 2.
Since ER–mitochondrial Ca2+ transfer occurs at the
MAMs, it is not surprising that several intracellular
Ca2+-transport systems reside at the MAMs. Both the
IP3R and VDAC1 can be found at the MAMs, where they
are connected to each other via glucose-related protein of
75 kDa (GRP75)55. Interestingly, isoform-speciﬁc func-
tions for these channels at the MAMs have been dis-
covered. Overexpression of VDAC1, VDAC2, as well as
VDAC3 increased mitochondrial Ca2+ uptake, yet pro-
apoptotic Ca2+ signals were only enhanced by VDAC1
overexpression63. Moreover, VDAC1 is the only VDAC
isoform that co-immunoprecipitated with the IP3R
63.
Similarly, IP3R3 seems to be the isoform that pre-
ferentially transmits pro-apoptotic Ca2+ signals to the
mitochondria via the MAMs64,65. Not only Ca2+-release
channels are located at the MAMs, the sarco-/endo-
plasmic reticulum Ca2+ ATPase (SERCA) pump localizes
to the MAMs as well66–68. SERCA pumps can inﬂuence
the properties of the MAMs since their activity deter-
mines how fast Ca2+ is cleared from the micro-domain69.
Moreover, SERCA pumps critically affect apoptotic sen-
sitivity by controlling the steady-state ﬁlling level of the
ER Ca2+ stores, which is determined by the balance
between ER Ca2+ leak and ER Ca2+ uptake66,69–72. Also
for SERCA, isoform-speciﬁc functions exist: ER stress
causes induction of SERCA1T, a truncated splice-variant
of SERCA1. SERCA1T is a determinant of ER leakiness,
ER
Mitochondrion
IP R
VDAC1 MCU
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FATE1
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Fig. 2 Regulation of ER–mitochondrial Ca2+ signaling by
oncogenes and tumor suppressors at the MAMs. Arrow-headed
full lines indicate a stimulatory effect, while bar-headed full lines
indicate an inhibitory effect. Dot-headed lines indicate a tethering or a
spacing effect, depending on the inward- or outward-facing dots,
respectively. ER–mitochondrial Ca2+ transfer at the MAMs can be
altered by different ﬁne-tuning mechanisms. These mechanisms often
involve oncogenes and tumor suppressors. An important tool to
regulate the activity of the Ca2+ signaling proteins at the MAMs is
phosphorylation. Akt/PKB-mediated phosphorylation is known to
suppress Ca2+ release via the IP3R. However, this phosphorylation is
counteracted by both PTEN, in a direct way, and PP2A, in an indirect
way. This indirect mechanism consists of recruitment of PP2A to the
IP3R via PML. In turn, PP2A deactivates Akt/PKB by dephosphorylation
and this relieves IP3R inhibition. In addition, Ca
2+-signaling proteins
like IP3R, VDAC1, and SERCA interact with other proteins, which
change their Ca2+-signaling properties. Bcl-2-protein family members
are among these proteins altering Ca2+ signals at the MAMs. Bcl-2
binds to the IP3R, inhibiting pro-apoptotic Ca
2+ signaling, while Bcl-Xl
interacts with VDAC1, inhibiting Ca2+ uptake through the OMM. p53, a
master regulator of cell fate, on the other hand, interacts with SERCA,
changing its oxidation state, thereby enhancing reuptake of Ca2+ in
the ER. A third category of proteins that modiﬁes Ca2+ signaling at the
MAMs are those proteins that change the properties of the MAMs, e.g.
ER-to-mitochondria distance at the MAMs. Mfn-2 in the ER is able to
interact with Mfn-1 or Mfn-2 at the OMM, thereby tethering both
organelles. On the other hand, there is FATE1 which has the opposite
effect, namely spacing the mitochondria and the ER. The distance
between ER and mitochondria at the MAMs is determined by these
tethers and spacers and this, in turn, regulates the efﬁciency of
ER–mitochondrial Ca2+ transfer
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thereby promoting Ca2+ transfer to the mitochondria and
thus supporting pro-apoptotic Ca2+ signaling73,74.
As will be discussed further on, expression levels of the
Ca2+-signaling proteins critically determine the cell’s Ca2+
-signaling properties. Furthermore, ER–mitochondrial Ca2+
signaling is ﬁne-tuned by various oncogenes and tumor
suppressors75,76. These proteins may induce post-
translational modiﬁcations that alter the Ca2+-signaling
properties of proteins at the MAMs77. Particularly, phos-
phorylation of the IP3R is a critical factor: Akt/protein
kinase B (PKB) suppresses IP3R-mediated Ca
2+ release
through phosphorylation78, while tumor suppressors PTEN
(direct dephosphorylation of IP3R)
57 and PML (indirect
dephosphorylation via sequestration of protein phosphatase
2A (PP2A) and subsequent Akt/PKB inhibition)56 counter-
act this. Also, SERCA is a target for post-translational
modiﬁcation: p53 changes SERCA’s oxidative state, pro-
moting its ER Ca2+-uptake activity and thus altering the net
ﬂux of Ca2+ released from the ER66,79,80.
In addition, complex formation between Ca2+-transport
proteins like IP3Rs and VDAC1 at the MAMs and tumor
suppressors or oncogenes inﬂuences ER–mitochondrial
Ca2+ transfer. Notably, several Bcl-2-protein family
members, critical regulators of apoptosis, were shown to
be present at the MAMs81,82 and can modify IP3R-
mediated Ca2+-release77,83,84. Bcl-2, an anti-apoptotic
protein of the Bcl-2-protein family, inhibits the IP3R
directly by binding with its Bcl-2 homology (BH)
4 domain to the central, modulatory domain of the
IP3R
85–87. The BH4 domain also participates in overall
stability of the Bcl-2 protein, affecting its IP3R-inhibitory
properties88. Bcl-2’s transmembrane domain is necessary
for efﬁcient in cellulo IP3R inhibition
89. Indirectly, Bcl-2
changes IP3R activity by providing a docking place at the
IP3R for protein phosphatase 1 (PP1), which inhibits IP3R
function by dephosphorylating the receptor90. Bcl-2 also
regulates IP3R function by docking dopamine- and
cAMP-regulated phosphoprotein of 32 kDa, a PP1 inhi-
bitor, and the protein phosphatase calcineurin in a com-
plex on the IP3R
91. Thus, IP3R activity is regulated by a
negative feedback mechanism that prevents excessive,
pro-apoptotic Ca2+ release from the ER. Besides Bcl-2,
also Bcl-Xl and Mcl-1 can modulate IP3R activity
92–94. An
extended discussion on the modulation of Ca2+ signaling
by Bcl-2-protein family members can be found
elsewhere82,95.
Besides the IP3Rs, Bcl-2-family members can also target
mitochondrial Ca2+-transport systems, including VDAC1.
VDAC1/Bcl-2 complex formation inhibits VDAC1’s
function in mitochondrial Ca2+ transport96,97. The BH4
domain of Bcl-2 appeared to play a critical role in VDAC1
regulation98. Follow-up work revealed that the BH4
domain of Bcl-Xl is more effective in targeting and
modulating VDAC1 than the BH4 domain of Bcl-281.
Consequently, while both the BH4 domains of Bcl-2 and
Bcl-Xl could prevent mitochondrial Ca2+ uptake, BH4-
Bcl-2 acted at the level of IP3Rs, while BH4-Bcl-Xl acted
at the level of VDAC181. To summarize,
ER–mitochondrial Ca2+ transfer at the MAMs can be
inﬂuenced through IP3R-mediated Ca
2+ release, VDAC1-
mediated mitochondrial Ca2+ uptake, or modulation of
the SERCA activity.
In addition to this, ER–mitochondrial Ca2+ transfer is
altered by the number of MAMs and the distance between
the ER and the OMM at the MAMs99,100. Proteins that
hold both membranes together are typically called tethers.
An example of a tether at the MAMs is the GTPase Mfn-2
involved in mitochondrial fusion. Mfn-2 tethers ER and
mitochondria through homo- and heterotypic interac-
tions with Mfn-2 and Mfn-1, respectively59,101. The
importance of tethering was shown in Mfn-2-knockout
cells, where ER–mitochondrial Ca2+ transfer was severely
reduced101. Yet, the role of Mfn-2 as a tether has been
debated, since another study showed that ablation of Mfn-
2 does not impair the ER–mitochondrial connection but
contrarily, tightens it58,101. Here, Mfn-2 was proposed as a
spacer that increases the distance at the MAMs and
reduces ER–mitochondrial signaling. A typical spacer is
FATE1, a cancer testis antigen, which is normally only
expressed in the testis61. However, in certain cancers,
FATE1 becomes upregulated and causes MAMs
alterations61.
Rewiring Ca2+ signaling in cancer cells
The different possible layers of regulation of Ca2+ sig-
naling impart an enormous ﬂexibility to the cell concerning
ﬁne-tuning cellular processes in response to internal and
external stimuli. However, this sensitive system can be
hijacked to drive malignant transformations in the cell6. It
is known that several types of cancer cells undergo an
extensive rewiring of their Ca2+-signaling machinery,
favoring oncogenesis6,102,103. At the level of the ER and the
mitochondria, expression levels of Ca2+-signaling proteins,
including VDAC1, IP3R, and SERCA, are often altered in
cancer cells. For instance, VDAC1 expression levels are
correlated with tumor growth and invasion in several types
of cancer, e.g. non-small cell lung cancer and cervical
cancer104,105. In this regard, recently, genetic disruption of
VDAC1 in cells from cancer xenograft models displayed
decreased mitochondrial membrane potential and ATP
content with a consequent low migration rate and tumor
regression106,107. Another example includes IP3R1 down-
regulation in bladder cancer cells, which attenuates
cisplatin-mediated apoptosis through a decrease in
ER–mitochondrial Ca2+ uptake, preventing mitochondrial
Ca2+ overload108,109. Remodeling of Ca2+ signaling in
tumorigenesis is also documented by the signiﬁcant
reduction or loss of the SERCA3 isoform in transformed
Kerkhofs et al. Cell Death and Disease Page 5 of 15
Ofﬁcial journal of the Cell Death Differentiation Association
UN
CO
RR
EC
TE
D P
RO
OF
colonic epithelial cells110. Different mechanisms may be
responsible for the change in expression levels. Recently,
two novel mechanisms dysregulated in several cancer types
have been discovered to impact the proteasomal turnover
and thus stead-state expression levels of IP3R3 and the
apoptotic sensitivity of cells111. (i) The tumor suppressor
PTEN competes with F-box/LRR-repeat protein 2 (FBXL-
2), an E3 ubiquitin ligase component belonging to the Skip-
Cullin1-F-box protein family112, for binding to IP3R3,
thereby slowing down FBXL-2-mediated proteasomal
degradation of IP3R3
113. This represents a novel mechan-
ism by which loss of PTEN allows cancer cells to evade
apoptosis, since pro-apoptotic mitochondrial Ca2+ transfer
becomes impaired due to downregulation of the IP3R3.
(ii) The tumor suppressor BRCA1-associated protein
1 (BAP1), a deubiquitylating enzyme, promotes
ER–mitochondrial Ca2+ transfer by stabilizing the IP3R3
114.
BAP1 function is particularly impaired during prolonged
environmental stress, associated with acquired inactivating
mutations in BAP1 genes. Loss of BAP1 results in IP3R3
downregulation, hampering the effective apoptotic clear-
ance of damaged cells and favoring oncogenesis and
malignant cell survival.
While MCU is not residing at the MAMs, its expression
can be controlled in a tumor-speciﬁc manner, e.g. via
microRNAs (miR)115. As such, miR-25, targeting MCU,
was overexpressed in colon cancer cell lines and tumor
samples, decreasing MCU expression compared to non-
tumorigenic cells. Moreover, miR-25 overexpression in
HeLa cells reduced mitochondrial Ca2+ accumulation,
resulting in apoptosis resistance. In contrast, antagonizing
miR-25 expression using antagomirs re-sensitized colon
cancer cells to Ca2+-dependent apoptotic stimuli, like
H2O2 and ceramide. Interestingly, MCU may prevent
tumor cell survival in an early stage, but can become a
pro-malignant factor in late-stage tumors, like triple
negative breast cancer cells116. These cells express high
levels of MCU, correlating with tumor size and lymph
node inﬁltration, which negatively impact survival out-
come. The mechanisms involved MCU-dependent uptake
of Ca2+ into the mitochondrial matrix and subsequent
generation of ROS that stabilized hypoxia-inducible fac-
tor-1α, a transcription factor driving the expression of
genes involved in cancer migration and invasion116,117.
Furthermore, oncogenes like Akt/PKB and FATE1, and
tumor suppressors like PML and PTEN, can play additional
roles in the development of cancer via Ca2+-signaling
modulation108. A striking example of this is apoptotic
resistance. Since mitochondrial Ca2+ overload is involved
in apoptotic cell death, modifying ER–mitochondrial Ca2+
transfer at the MAMs alters apoptotic sensitivity48. Cancer
cells can gain resistance against cell death, e.g. by over-
expressing proteins that suppress IP3R-mediated Ca
2+
signaling, like Akt78, or by increasing the intermembrane
distance at the MAMs (e.g. FATE1), thereby rendering
ER–mitochondrial Ca2+ transfer less efﬁcient61. These
mechanisms are not only supporting basic cancer cell
characteristics, but also underlie resistance against che-
motherapy. Cell death induction strategies still play a
central role in the ﬁght against cancer. While selective
oncogene inhibitors, like venetoclax/ABT-199 for Bcl-2
inhibition, emerged and entered the clinic118, chemother-
apy remains a very effective way to eradicate tumor cells by
triggering cell death119.
Besides ER–mitochondrial Ca2+ signaling, Ca2+ ﬂuxes
across the plasma membrane can affect cancer properties
as well. We would like to refer to other excellent reviews
regarding this topic120–122, as in this section, we would
like to focus on chemotherapeutic drugs that act on Ca2+
signaling at the MAMs.
Chemotherapy and Ca2+ signaling in cancer cells
Ca2+ signaling appears to be a major contributor to the
cytotoxic effects of chemotherapy. Many chemotherapeutic
agents trigger a rapid onset of cytosolic [Ca2+] rises123.
Furthermore, shifts in cytosolic [Ca2+] have been proposed
as early markers for cytotoxicity in cells in response not
only to H2O2 or staurosporine but also to chemother-
apeutics like gossypol or arsenic trioxide (ATO)123. The
mechanism of these early cytosolic [Ca2+] elevations is not
always fully understood, but may in part depend on the
presence of p53. Upon chemotherapeutic treatment,
extra-nuclear p53 can accumulate at the ER membranes
where it binds SERCA and activates its ER Ca2+-uptake
activity66,79, 80,124,125. Thus, SERCA activation will augment
the ER Ca2+-store content, overﬁlling the ER with Ca2+ and
thus increasing the likelihood for spontaneous ER Ca2
+-release events126. However, the occurrence of shifts in
cytosolic [Ca2+] may not be a general phenomenon, as on-
target Bcl-2 inhibitors, like ABT-737127 and venetoclax/
ABT-199128, do not trigger these early cytosolic [Ca2+]
elevations, even not in cancer cells that are dependent on
Bcl-2 for their survival. The reason for these varying
responses are not fully understood, but may actually relate
to the mechanism of action of the drug applied and in
particular whether p53 is involved.
Here, we will discuss the chemotherapeutic agents that
act via ER–mitochondrial Ca2+ signaling. These che-
motherapeutics are summarized in Table 1, whereas a
schematic representation of their function at the MAMs is
provided in Fig. 3.
Arsenic trioxide
Acute promyelocytic leukemia (APL) is almost always
characterized by a t(15;17) chromosomal translocation,
resulting in a PML/retinoic acid receptor (RAR) α fusion
protein that hinders the differentiation of hematopoietic
cells by inhibiting gene transcription129,130. APL patients
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are mostly treated by a combination of all-trans retinoic
acid and ATO therapy, which stimulates APL cell differ-
entiation by triggering proteasomal degradation of the
PML/RARα fusion protein129,131–133. This treatment
approach results in high APL cure rates, reﬂected by
high complete remission and overall survival
percentages129,132.Ta
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Fig. 3 The action of chemotherapeutic agents at the MAMs.
Arrow-headed full lines indicate a stimulatory effect, while bar-headed
full lines indicate an inhibitory effect. Dashed lines indicate an indirect
effect. Dot-headed lines indicate a tethering or a spacing effect,
depending on the inward- or outward-facing dots, respectively. This
ﬁgure constitutes an overview of the chemotherapeutics discussed in
this review and how they act on the MAMs. Resveratrol is an inhibitor
of the ATP synthase. This inhibitory effect leads to less ATP being
available for SERCA pumps to ensure rapid reuptake of Ca2+ in the ER,
creating a high local Ca2+ concentration. This, together with an
increased ER–mitochondrial tethering, underlies the cancer cell-
speciﬁc killing of resveratrol. ATO, another chemotherapeutic agent,
increases PML levels at the MAMs. This restores ER–mitochondrial Ca2+
transfer in cancer cells that have a decreased or impaired PML activity
and consequently suppresses pro-survival autophagic ﬂux. A third
chemotherapeutic drug, cisplatin, covalently binds to DNA, inducing
DNA damage and causing apoptotic cell death, involving
ER–mitochondrial Ca2+ signaling. However, cancer cells
overexpressing Bcl-2 are more resistant to cisplatin-induced cell death,
seemingly via a dual mechanism: the inhibition of Ca2+ release from
the ER and the inhibition of an increase in ER–mitochondrial contact
points resulting from cisplatin treatment. In this sense, administering
ABT-737, a Bcl-2-inhibiting BH3 mimetic, to cancer cells, restored
sensitivity to cisplatin. Furthermore, there is adriamycin, which renders
ER–mitochondrial Ca2+ transfer more efﬁcient by enriching p53 at the
SERCA pumps. This leads to an increased activity of SERCA, increasing
the ER Ca2+ levels and sensitizing cells towards apoptosis. Lastly,
mitotane is an inhibitor of SOAT1, resulting in increased free
cholesterol and lipid-induced ER stress. However, sensitivity towards
mitotane is dependent on the expression levels of FATE1, a spacer
protein at the MAMs. Increased levels of FATE1 are responsible for
decreased mitochondrial Ca2+ uptake and in this way render cancer
cells less sensitive towards apoptosis
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ATO also inﬂuences ER–mitochondrial Ca2+ signaling,
thereby repressing autophagy in cancer cells17. Autophagy
is an important pro-survival pathway in malignant cells
that experience oncogenic stress, as missing nutrients can
be delivered to the cells via this process17,134. The tumor
suppressor PML, which is localized at the MAMs,
represses autophagy by promoting ER–mitochondrial Ca2
+ transfer and mitochondrial respiration17. Hence, PML is
often downregulated in cancer cells135. Loss of PML
results in reduced IP3R-mediated Ca
2+ transfer from the
ER to the mitochondria, leading to decreased mitochon-
drial Ca2+ levels, thereby diminishing mitochondrial
respiration and ATP production17. This triggers activation
of AMP-activated protein kinase, which stimulates pro-
survival autophagy by a mechanism involving mechanistic
target of rapamycin and unc-51-like kinase 1 path-
ways136,137. Interestingly, this autophagic process is
repressed in APL cells treated with ATO17. Short-term
treatment of these cells with ATO promotes the selective
degradation of the PML/RARα fusion protein, but not of
PML. Furthermore, exposure to ATO increases the PML
levels at ER–mitochondria contact sites in a p53-
dependent manner (Fig. 3). Besides a block in autop-
hagy, ATO-treated cells also displayed reduced resistance
to metabolic stress17. Furthermore, this study implicates
that the response of tumor cells characterized by loss of
PML to chemotherapeutic agents can be improved by
inhibiting autophagy.
Cisplatin
Cisplatin is a chemotherapeutic agent used to treat
numerous human cancers, including lung, ovarian, head
and neck, bladder, and testicular cancer138. The antic-
ancer activity of this platinum-based drug has been linked
to its ability to covalently bind purine residues on
DNA138,139. This interaction causes DNA damage, inter-
feres with DNA repair mechanisms, and blocks cell divi-
sion, ultimately leading to apoptotic cell death.
Unfortunately, cisplatin treatment has been associated
with considerable side effects, like cardiotoxicity, hepa-
totoxicity, nephrotoxicity, and toxicity of other organs,
and drug resistance is often acquired during therapy as
well138. To overcome these obstacles, combination
therapies of cisplatin with other anti-cancer drugs,
including paclitaxel, doxorubicin, and gemcitabine, form
the basis for treatment of many human cancers138.
Interestingly, the ER–mitochondrial Ca2+ signaling
pathway contributes to cisplatin-induced cell death.
Treatment of SKOV3 human ovarian cancer cells with
cisplatin increased the number of ER–mitochondria con-
tact sites, causing a Ca2+ ﬂow from the ER to the mito-
chondria (Fig. 3)140. This resulted in high mitochondrial
Ca2+ levels, which triggered apoptosis in the cisplatin-
treated ovarian cancer cells. Furthermore, the expression
level of the anti-apoptotic protein Bcl-2, which is over-
expressed in many tumors and drives tumorigenesis and
chemoresistance, seems to be a determinant for the sen-
sitivity of cancer cells to cisplatin (Fig. 3). In non-small
cell lung cancer and bladder cancer, cisplatin sensitivity
could be enhanced by downregulating Bcl-2141,142. In
addition, downregulation of Bcl-2 in SKOV3 cells with
siRNA increased the cytoplasmic and mitochondrial Ca2+
levels as well as the number of ER–mitochondria contact
points after cisplatin treatment, thereby increasing the
sensitivity to the chemotherapeutic agent143. Hence, Bcl-2
seems to form a potential therapeutic target to improve
cisplatin therapy of ovarian cancer cells. Additionally, in
neuroblastoma cells, cisplatin-induced cell death was
preceded by a rise in cytosolic [Ca2+]144. Cisplatin treat-
ment also increased the expression levels of several
Ca2+-transport systems, including IP3R3, RyR3, and the
S100 Ca2+-binding protein A6. Therefore, cisplatin-
induced cell death can be enhanced by pharmacological
modulators of Ca2+-regulatory proteins, like the SERCA
inhibitor thapsigargin144.
BH3 mimetics
BH3 mimetics are a class of anti-cancer drugs inhibiting
the function of anti-apoptotic Bcl-2-protein family
members like Bcl-2, Bcl-Xl, and Mcl-1145–147,148. This
causes pro-apoptotic Bcl-2-family members, which are
sequestered by their anti-apoptotic counterparts through
a hydrophobic cleft, consisting of the BH1, BH2, and BH3
domain, to be released, resulting in apoptosis145,146. This
is an effective anti-cancer therapy in cancers that rely on
an upregulation of the anti-apoptotic Bcl-2-family pro-
teins for their survival. Several molecules have been
developed as BH3 mimetic drug, notably ABT-737, which
targets the hydrophobic cleft of both Bcl-2 and Bcl-Xl, its
orally available analog ABT-236 (navitoclax) and ABT-
199 (venetoclax), which solely targets the hydrophobic
cleft of Bcl-2145. While these drugs are speciﬁcally
developed to suppress the canonical, anti-apoptotic
function of the Bcl-2-protein family members at the
mitochondria, it seems that their intracellular effects are
more complex.
Thrombocytopenia is an important side effect caused by
ABT-737 and ABT-263, since these BH3 mimetic drugs
inhibit the function of Bcl-Xl, which is essential for pla-
telet formation and survival149–151. Dysregulation of
intracellular Ca2+ homeostasis might underlie ABT-737-
and ABT-263-induced thrombocytopenia, as addition of
ABT-263 to platelets triggered an acute rise in cytosolic
Ca2+ levels149. However, a direct link between deranged
Ca2+ signaling and platelet dysfunction was not provided
since this effect was only observed upon addition of
relatively high ABT-263 concentrations (10 µM), whereas
platelet function was already decreased at much lower
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concentrations (100 nM–1 µM)149. Furthermore, pro-
longed treatment of platelets with ABT-263 and ABT-737
depleted the intracellular Ca2+-storage organelles149,152.
However, it was not clear whether the effects on Ca2+
signaling were the cause of platelet apoptosis or whether
they were the consequence of platelets being in late-stage
apoptosis due to Bcl-Xl inhibition. Our lab excluded a
direct impact of ABT-737 on intracellular Ca2+ signaling,
since ABT-737 application did not affect thrombin-
induced Ca2+ signaling in platelets nor ATP-induced
Ca2+ signaling in HeLa cells127. Moreover, SERCA activity
and IP3R-mediated Ca
2+ release were unaffected by ABT-
737. These results argue against a proximal role of Ca2
+-signaling dysregulation in platelet dysfunction and
apoptosis induced by ABT-737.
On the other hand, for ABT-199/venetoclax, which only
targets the hydrophobic cleft of Bcl-2, no evidence was
found for a perturbation of Ca2+ homeostasis128,148,153. In
several human and mouse cell models, ABT-199 did not
trigger cytosolic Ca2+ release events by itself nor did it
affect agonist-induced IP3R-mediated Ca
2+ signaling128.
Also, clearance of Ca2+ from the cytosol after agonist
application was not affected. Furthermore, ABT-199 did
not interfere with the inhibition of IP3R caused by over-
expression of Bcl-2128. Nevertheless, it seems that there is
an interplay between ABT-199-induced cell death in Bcl-
2-dependent cancer cells and basal Ca2+ signaling, since
chelating intracellular Ca2+ using BAPTA-AM enhanced
ABT-199-induced cell death128. The mechanisms under-
lying this phenomenon remain unclear, but might be due
to downregulation of anti-apoptotic Bcl-2-family mem-
bers or upregulation of pro-apoptotic Bcl-2-family
members. Furthermore, Bcl-2-dependent cancer cells
can be sensitized towards ABT-199 by the application of
BIRD-2154, a BH4-domain inhibitor of Bcl-2 that triggers
toxic Ca2+-release events and apoptosis in various cancer
cells, including chronic lymphatic leukemia, diffuse large
B-cell lymphoma, multiple myeloma, follicular lymphoma,
and lung cancer cells86,154–156. Further, it appears that
BIRD-2 upregulates Bim in a Ca2+-dependent manner,
thereby likely accounting for an increased sensitivity of
the cells towards BH3 mimetics like ABT-199 applica-
tion154,157. As such, BIRD-2 and ABT-199 can act syner-
gistically to trigger cell death in Bcl-2-dependent cancers.
Finally, it appears that cancer cells that are less sensitive
to BH3 mimetics are more sensitive to BIRD-2 and vice
versa154,156,157.
Interestingly, ABT-737 can enhance the chemother-
apeutic effectivity of cisplatin in cholangiocarcinoma (CC)
as well as in ovarian cancer cells143,158. In the latter, ABT-
737 treatment increased the cisplatin-induced growth
inhibition and apoptosis in cisplatin-resistant cells, hence
restoring their sensitivity to the chemotherapeutic
agent143. Combination therapy with cisplatin and ABT-
737 of the cisplatin-resistant ovarian cancer cells
increased the number of ER–mitochondria contact sites
induced by cisplatin, stimulating Ca2+ transfer from the
ER to the cytosol and the mitochondria (Fig. 3). Hence,
ABT-737 can reverse cisplatin resistance of ovarian can-
cer cells by enhancing ER-associated and mitochondria-
mediated apoptosis143. Furthermore, ABT-737 sensitized
CC cells to cisplatin therapy by regulating mitochondrial
dynamics158. ABT-737 stimulated CC cells to undergo
apoptosis after cisplatin treatment by promoting mito-
chondrial ﬁssion and inducing mitophagy. Therefore,
ABT-737 combined with cisplatin might be an effective
strategy to treat CC patients158. This also provokes the
question in what manner Bcl-2-protein family members
regulate the dynamics of the MAMs in cancer.
Of note, earlier versions of Bcl-2-inhibiting molecules
can dysregulate intracellular Ca2+ homeostasis. HA14-1
and stabilized HA14-1s can deplete ER Ca2+ stores by
inhibiting the SERCA Ca2+ pump127,159. In a separate
study, both HA14-1 and BH3I-2′ trigger Ca2+ release
from the ER of pancreatic acinar cells through IP3R- and
RyR-mediated mechanisms, elevating cytosolic Ca2+
levels, a feature that contributes to their cell death
properties160. Here, it was proposed that dissociation of
Bax from Bcl-2 using these drugs sensitize IP3Rs and RyRs
to cytosolic Ca2+. Excitingly, the ability of HA14-1 and
BH3I-2′ to increase cytosolic Ca2+ levels in pancreatic
acinar cells was strictly dependent on the presence of Bax,
while the presence of Bcl-2 and Bak was not critical for
this process. It was proposed that Bax, released from Bcl-
2, can induce Ca2+ leak from the ER, either by itself or by
acting on ER Ca2+-leak channels like IP3Rs
161. Yet, fur-
ther work using selective Bcl-2 inhibitors is needed to
validate this model. A detailed discussion on the role
of BH3 mimetics and Ca2+ signaling is provided
elsewhere148,162.
Resveratrol
Resveratrol is a natural polyphenol produced in
response to stressful conditions by various plant species.
It is found in several foodstuffs, including grapes, mul-
berries, and peanuts, and has been attributed beneﬁcial
health effects since the early 1990s163–165. It is known as a
multi-target agent exhibiting antioxidant, anti-inﬂamma-
tory, and immunomodulatory activities. This pleiotropic
compound affects cell proliferation, differentiation,
apoptosis, and autophagy and attenuates many age-
related chronic complications, such as metabolic,
cardiovascular, and neurodegenerative diseases164,165.
Furthermore, resveratrol has been used as a chemopre-
ventive and chemotherapeutic agent in many types of
cancer163–165. For instance, it has been used in clinical
trials conducted in patients with colon, colorectal, and
gastrointestinal cancers as well as in a trial examining the
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effects of resveratrol in the prevention of cancer in healthy
participants163. Remarkably, resveratrol functions as a
speciﬁc anticancer agent with limited toxicity in normal
cells163. However, the exact mechanism by which resver-
atrol speciﬁcally kills cancer cells remains unclear.
Recently, it was suggested that the difference in ATP
demand between cancer and somatic cells underlies the
cancer cell-speciﬁc toxicity of resveratrol166. Cancer cells
are characterized by a very high ATP demand at the ER
because of immense protein folding activities going on at
this organelle167,168. Therefore, tethering of the ER and
the mitochondria, which produce ATP via the ATP syn-
thase localized in the IMM, is strongly enriched in cancer
cells, warranting high ATP levels in the proximity of the
ER169,170. However, resveratrol, which acts as an inhibitor
of the F1 subunit of the ATP synthase171–174 exploits the
enhanced ER–mitochondria coupling in malign cells to
kill these cells exclusively (Fig. 3). As a result of ATP
synthase inhibition in resveratrol-treated cells, ATP for-
mation is reduced, by which the high energy demand of
cancer cells is not met anymore166. As a consequence of
the reduced ATP content at the mitochondria, SERCA
activity within the MAMs is decreased, hampering Ca2+
reuptake into the ER, provoking not only an accumulation
of Ca2+ in the micro-domain between ER and mito-
chondria166, but also leading to a depletion of the ER via
the Ca2+-leak channels175. Both phenomena result in a
high local Ca2+ concentration and because of the
enforced ER–mitochondria coupling in cancer cells,
mitochondrial Ca2+ accumulation is consequently
enhanced upon treatment with resveratrol. Due to the fact
that cancer cells are more sensitive to ATP synthase
inhibition than healthy cells, resveratrol will especially
trigger apoptotic cell death via mitochondrial Ca2+
overload in those cells166.
Adriamycin
Adriamycin, also known as doxorubicin, is an
anthracycline-type drug that has been used in cancer
therapy for many years176,177. It is characterized by a
broad-spectrum antineoplastic activity, although its
mechanism of action is complex. Adriamycin inhibits
topoisomerase II, intercalates in DNA, and generates free
radicals, hence inhibiting biosynthesis of macromolecules
and leading to oxidative stress177–179. Ultimately, adria-
mycin treatment results in apoptotic cell death. This
chemotherapeutic agent is commonly used to treat var-
ious types of cancer, including breast, ovarian, bladder,
stomach, and lung cancer177. However, the applicability of
adriamycin as anticancer therapy is restricted due to its
severe toxic effects in healthy tissues176,177,179. Especially
cardiotoxicity forms a major concern during adriamycin
therapy, limiting the dose that can be administered to
patients177,180. To circumvent the adverse effects of
adriamycin, several drug delivery systems have been
used176,177,179. For instance, adriamycin-induced toxicity
is decreased when using liposomal, nanoparticle, or
hydrogel drug formulations.
Adriamycin also renders cells more prone to
programmed cell death by inﬂuencing the ER–
mitochondrial Ca2+ signaling axis66,79,181. The tumor
suppressor p53, an important transcription factor reg-
ulating DNA repair, cell-cycle arrest, and apoptosis,
modulates Ca2+ homeostasis by stimulating the SERCA
pump located at the ER and the MAMs66. As a con-
sequence, Ca2+ accumulation in the ER is enhanced.
Interestingly, treatment of cancer cells with adriamycin
caused an enrichment of p53 at the ER and the MAMs
(Fig. 3)66,79. This induction of p53 by adriamycin led to
higher ER Ca2+ levels and higher cytosolic and mito-
chondrial [Ca2+] increases evoked by agonist stimula-
tion66. Moreover, Ca2+ transport from the ER to the
mitochondria was increased by adriamycin, allowing
apoptotic stimuli to rapidly overload the mitochondria
with Ca2+, resulting in apoptotic cell death. Hence,
chemotherapeutic agents like adriamycin boost toxic
ER–mitochondrial Ca2+ signaling through modulation of
the Ca2+ homeostasis at the MAMs, thereby triggering
apoptotic cell death in cancer cells66,79.
Another way in which Ca2+ signaling is able to con-
tribute to the sensitivity of cancer cells to chemother-
apeutics, is the induction of autophagy182. Recently,
valproic acid was found to reduce the intracellular
availability of IP3, hence blocking Ca
2+ transfer to the
mitochondria and altering the AMP-activated protein
kinase 1/2–mechanistic target of rapamycin pathway.
This lack of ER–mitochondrial signaling induced
autophagy, thereby sensitizing cancer cells to
adriamycin182.
Lipid-interfering strategies
A recent insight in tumor biology is the occurrence of
dysregulation of lipid metabolism in cancer cells and its
importance to several aspects of cancer cell function and
survival. Consequently, disrupting or altering lipid
homeostasis in cancer cells might be an efﬁcient way of
inducing cell death183. One of the ways to induce apop-
tosis in this manner in cancer cells is the use of
chemotherapeutics that increase intracellular, free cho-
lesterol183. Alkyl phospholipids were observed to hinder
cholesterol transport from the mitochondria to the ER,
avoiding its esteriﬁcation, whereas cholesterol synthesis
and incorporation was increased at the same time in
glioblastoma cells184. In macrophages it was found that
this free cholesterol accumulates at the ER, inhibiting
SERCA pumps and causing depletion of the ER. This
results in an increased transfer of Ca2+ to the mito-
chondria and subsequent apoptosis185.
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Another chemotherapeutic drug that acts on lipid
metabolism is mitotane, a derivative of the insecticide
dichlorodiphenyl-trichloroethane. Mitotane is the only
chemotherapeutic drug approved for the treatment of
adrenocortical carcinoma (ACC), one of the deadliest
endocrine malignancies186–189. In ACC cells, but not in
non-adrenal cancer tissues, mitotane counteracts tumor
growth and steroid hormone production186,190. These
effects of mitotane are believed to be the result of the
inhibition of the sterol-O-acyl-transferase 1 (SOAT1), an
enzyme that protects cells against the harmful effects of
free cholesterol by transforming it into cholesterol esters.
Because of SOAT1 inhibition, mitotane therapy leads to
the accumulation of toxic lipids, including free cholesterol
and oxysterols, inside ACC cells, which triggers lipid-
induced ER stress190. Moreover, in ACC tissue samples,
SOAT1 expression correlated with the response to
mitotane treatment.
Interestingly, mitotane-induced apoptosis in ACC cells
also depends on FATE1 expression61. Under physiological
conditions, FATE1 expression is restricted to the testis and
adrenal gland, while FATE1 overexpression is observed in a
variety of cancers191,192. In ACC cells, FATE1 expression is
controlled by the steroidogenic factor-1 (SF-1), a tran-
scription factor that is important for adrenal development
and plays a role in the formation of adrenocortical
tumors61,191. FATE1, localized at the MAMs where it
uncouples the ER and mitochondria, decreases mitochon-
drial Ca2+ uptake in ACC cells61. In this way, FATE1
protects cancer cells from Ca2+-dependent apoptotic sti-
muli. Furthermore, FATE1 expression conferred mitotane
resistance to ACC cells, when this chemotherapeutic drug
was used in a dose that falls inside the therapeutic window
for ACC patients, whereas knockdown of FATE1 in these
cells increased the sensitivity to the drug61. FATE1 prob-
ably protects against mitotane-induced apoptosis because
of its localization in the MAMs61. Mitotane inhibits the
SOAT1 enzyme190, which is also localized in the MAMs,
resulting in the accumulation of toxic cholesterol lipids.
Hence, in the presence of FATE1 mitotane-mediated
SOAT1 inhibition may be less efﬁcient (Fig. 3)61. Inter-
estingly, FATE1 expression in ACC tumor cells can even
be used as a prognosis indicator since FATE1 expression
is inversely correlated with the overall survival of
ACC patients61.
Conclusion
In conclusion, MAMs form important intracellular
signaling platforms, allowing for Ca2+-encoded messages
between the ER and the mitochondria. This
ER–mitochondrial Ca2+ exchange can be altered during
cancer development to promote cancer hallmarks like
evasion of apoptosis, excessive cell proliferation, and a
metabolic rewiring. In addition, many chemotherapeutics
act via Ca2+ signaling at the MAMs (Fig. 3). Moreover,
chemotherapeutics can interfere with the function of
oncogenes and tumor suppressors, thereby altering
ER–mitochondrial Ca2+ transfer. In this sense, che-
motherapeutics that modify ER–mitochondrial Ca2+ sig-
naling can be used to increase the response of cancer cells
towards therapeutics that harbor a Ca2+ component in
their working mechanism.
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